What Are Wall Street Analysts' Target Price for Pfizer Stock?

Core Viewpoint - Pfizer Inc. is facing challenges with its stock performance, underperforming compared to broader market indices and peers, amid a disappointing revenue forecast for 2026 [2][4]. Company Overview - Pfizer Inc. is a leading global biopharmaceutical company based in New York, with a market capitalization of $139.3 billion. The company focuses on discovering, developing, and commercializing medicines and vaccines across various therapeutic areas, including oncology, vaccines, cardiology, immunology, rare diseases, and internal medicine. It gained significant attention for its COVID-19 vaccine and antiviral treatment developed in partnership with BioNTech [1]. Stock Performance - Over the past year, Pfizer's stock has declined marginally, while the S&P 500 Index has increased by approximately 13.9%. In the last six months, Pfizer's stock rose by 4.4%, compared to an 8.8% increase in the S&P 500 [2]. - Compared to the Invesco Pharmaceuticals ETF, which gained about 24.8% over the past year and 25.1% over the past six months, Pfizer's underperformance is evident [3]. Revenue Forecast - On December 16, Pfizer's shares fell more than 3% after the company issued a revenue forecast for 2026 that disappointed investors. The projected revenue range is $59.5 billion to $62.5 billion, with the midpoint below Wall Street's consensus estimate of $61.63 billion. This outlook raised concerns about slowing growth, particularly as demand for COVID-related products declines [4]. - For FY2025, analysts expect Pfizer's earnings per share (EPS) to improve marginally to $3.12 on a diluted basis. The company has a strong earnings surprise history, beating consensus estimates in each of the last four quarters [4]. Analyst Ratings - Among the 25 analysts covering Pfizer stock, the consensus rating is a "Moderate Buy," which includes seven "Strong Buy" ratings, one "Moderate Buy," 16 "Holds," and one "Strong Sell" [5]. - Recently, UBS analyst Michael Yee initiated coverage of Pfizer with a "Neutral" rating and set a price target of $25, indicating a cautious outlook on the stock [6].